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Abstract: 
 
Certain fatty acid amides from Echinacea spp. have demonstrated moderate to high cannabinoid 
activity. As a result, CB2 activation is currently hypothesized to be the basis of activity for 
immunomodulation by Echinacea spp. PPARγ, an orphan nuclear receptor and lipid sensor, is 
known to inhibit IL-2 production and be activated by fatty acid derivatives such as the 
endocannabinoids. In these investigations, we demonstrate that undeca-2E-ene-8,10-diynoic 
acid, an Echinacea angustifolia-derived alkylamide lacking affinity for the CB2 receptor, 
inhibits IL-2 secretion in Jurkat T cells through PPARγ activity at low micromolar 
concentrations (330 ng/mL). The IL-2 inhibition is reversed by the addition of the selective 
PPARγ antagonist T0070907. Additionally, we show that that undeca-2-ene-8,10-diynoic acid 
stimulates 3T3-L1 differentiation, a process dependent on PPARγ activity. These experiments 
demonstrate that PPARγ is involved in T cell IL-2 inhibition by undeca-2-ene-8,10-diynoic acid 
and suggest that cytokine modulation by the alkylamides is due to polyvalent activity. 
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Article: 
 
1. Introduction 
 
Peroxisome proliferator activated receptor gamma (PPARγ) is an orphan nuclear receptor that 
regulates transcription of target genes in response to the binding of small lipophilic ligands [1]. It 
was originally described as a compulsory target in differentiating adipocytes [2]. Later it was 
identified in other tissues [3] and a role in macrophage [4], dendritic cell [5] and T cell [6] 
activity was observed. Intriguingly, recent results suggest that endogenous cannabinoids such as 
anandamide and 2-arachidonoylglycerol are agonists of PPARγ [7], [8]. 
 
Recent work has demonstrated that several of the unsaturated alkylamides of Echinacea spp. 
exhibit significant affinity for the cannabinoid-2-receptor (CB2) [9] and that in the presence of 
these alkylamides, LPS-induced TNF secretion is down-regulated, a function of alkylamides 
targeting CB2 in macrophages [10]. Raduner et al., [11] confirmed the high CB2 affinity of the 
2,4-diene unsaturated isobutylamides (olefinic alkylamides). Moreover, this group also reported 
that the selective CB2 antagonist SR144528 is incapable of fully inhibiting increases in total 
cellular concentrations of Ca2+ in HL60 cells induced by 2-arachidonoylglycerol (2-AG) and 
alkylamides, suggesting the possibility of the involvement of a second receptor. Echinacea spp.-
derived alkylamides have been shown to inhibit IL-2 secretion by human T cells [12], but the 
basis of alkylamide-induced IL-2 inhibition has not yet been reported. 
 
PPARγ activation has recently been found to be responsible for IL-2 inhibition induced by the 
endocannabinoids [7], [8]. In addition, Christensen et al. [13] recently demonstrated that various 
fatty acids and alkylamides from the flowers of E. purpurea activated PPARγ at high 
concentrations (40–100 μM). Considering the structural similarity between 2-AG and 
alkylamides, we investigated the possibility of induction of PPARγ activity by the alkylamide 
undeca-2E-ene-8,10-diynoic acid isobutylamide (hitherto referred to as undecaenediynoic acid 
isobutylamide) found in E. angustifolia and Spilanthes acmella (Fig. 1) [14]. This 2-ene 
alkylamide, containing a diacetylinic tail, has previously been found to have negligible affinity 
for CB2 [11]. Utilizing the previously established models of IL-2 inhibition and 3T3-L1 
adipogenesis, we investigated the possibility that PPARγ is a target of undecaenediynoic acid 
isobutylamide, and that interaction of this alkylamide with PPARγ contributes to alkylamide-
induced IL-2 inhibition and adipocyte differentiation. 
 
 
Fig. 1. Undeca-2E-ene-8,10-diynoic acid isobutylamide (undecaenediynoic acid isobutylamide). 
 
2. Materials and methods 
 
2.1. Reagents 
 
The following materials, chemicals and reagents were used. All reagents were from Sigma-
Aldrich (St. Louis, MO) except the following: undeca-2E-ene-8,10-diynoic acid isobutylamide 
(MW 231.34; certificate of analysis verified identity by NMR and HPLC, and purity of ≥ 99% by 
HPLC lot #21235-501; (Chromadex Inc., Santa Anna, CA); troglitazone (MW 441.5; Rezulin, 
abbreviated as TZD, gift from Ron Morrison, UNCG, Department of Nutrition); T0070907 (MW 
277.7; Cayman Chemicals, Ann Arbor, MI); ethanol (AAPER, Shelbyville, KY); nanopure water 
(Nanopure Diamond D11931, Barnstead International, Thermolyne, Dubuque, IA); calf serum 
(Colorado Serum Co., Denver, CO); human IL-2 Duo Set ELISA Kit-DY202 (R&D Systems, 
Minneapolis, MN); Jurkat E6.1 cells (ATCC, Manassas, VA); 3T3-L1 preadipocytes (a gift from 
Ron Morrison); nitro-cellulose membranes (Bio-Rad, Hercules, CA); anti-human PPAR γ 
primary antibody (Aviva Systems Biology, San Diego, CA); and goat anti-rabbit conjugated to 
horse radish peroxidase (US Biological, Swampscott, MA). 
 
2.2. Immunodectection of PPARγ protein in Jurkat cells by Western blotting 
 
Cells were harvested (2 × 106 cells) and lysed by boiling for 5 min. Nuclear extracts were 
analyzed in a denaturing 10% polyacrylamide gel, electrotransferred to a supported nitro-
cellulose membrane, and immunoblotted with the PPAR γ primary antibody (Aviva Systems 
ARP32880_T100). The membranes were soaked in blocking buffer [5% nonfat dry milk diluted 
in Tris-buffered saline — 0.1% Tween-20 (TBS-T)] for 1 h at room temperature with the 
indicated primary antibody (1:10,000). After washing, membranes were developed with 
horseradish peroxidase-conjugated secondary antibodies and visualized with a chemiluminescent 
detection system (GE Healthcare/Amersham Biosciences, Buckinghamshire, England). A double 
band is the expected image resulting from this antibody. 
 
2.3. Fibroblast cell culture and differentiation 
 
3T3-L1 cells were cultured in DMEM plus 10% calf serum, 4 mM l-glutamine and 1 mM Na 
pyruvate. Cells were plated in 6 well plates in a total of 1.5 mL of medium and grown to 
confluence over 4–5 days. 48 h after confluence was achieved (day 0), insulin (10 μg/mL) was 
added to all wells except the insulin free control. On day 2, media was changed to contain FBS 
and the following treatment conditions, which were added to separate triplicate wells: 
undecaenediynoic acid isobutylamide (5.0 μg/mL, 7.5 μg/mL and 10 μg/mL); TZD positive 
control (10 μM); insulin negative control (10 μg/mL); and vehicle control (EtOH:DMSO 
0.4%:0.1%) were added. Every 2 days, medium and all reagents, including treatments, were 
replenished after a PBS wash. Experiment was halted on day 5, at which time adipogenesis was 
determined by photomicroscopy by morphology and the presence of the obvious prominent lipid 
vacuoles. Images were taken with a SPOT digital camera mounted on an Olympus BX60 
fluorescence microscope. 
 
2.4. Jurkat cell culture and IL-2 ELISA 
 
Human E6.1 Jurkat T cells were cultured in RPMI 1640 with 10% FBS, 2 mM l-glutamine and 
1 mM Na pyruvate. After serum starvation for 7 h, Jurkat cells were plated in 96 well culture 
plates at 1.25 × 105 cells/mL in RPMI 1640 (without phenol red) with 10% FBS. Cells were 
treated with PMA (1.25 ng/mL) and PHA (0.25 μg/mL) and the selective antagonist T0070907 
or DMSO vehicle was added to appropriate wells and incubated at room temperature for 15 min 
after which alkylamides and TZD were added. Plates were then incubated for 18 h. Cell 
supernatants were collected (100 µL) and assayed for IL-2 by ELISA (Human IL-2 Duo Set 
ELISA Kit). All test conditions were assayed in triplicate and verified with repeated experiments 
three times. 
 
2.5. Cell survival by XTT assay 
 
The cytotoxicity of undecaenediynoic acid isobutylamide was measured by the XTT colorimetric 
assay [15], which was performed on the same plated cells cultured for the IL-2 cytokine testing 
in dual ELISA/XTT assays. For the cell viability standard curve, unstimulated cells were plated 
in triplicate at 2.5 × 104, 2 × 104, 1.5 × 104, 7.5 × 103, 5.0 × 103, and 2.5 × 103 cells/well. After 
removal of 100 µL supernatant from all wells, 100 μL of 1 mg/mL of 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) plus 0.02 mM phenazine methosulfate 
(PMS), in medium was added. After 5 h incubation, ODs at 450 nm (Teacan Sunrise plate reader, 
Grödig, Austria) were measured and cell concentrations extrapolated from known cell 
concentrations in standard curve. Test conditions were assayed in triplicate and repeated in two 
experiments. 
 
2.6. Statistical analysis 
 
All data are expressed as means ± SE of experiments conducted in triplicate. Statistical analysis 
was performed using Student's t-test and analysis of variance (one-way ANOVA). The accepted 
level of significance was p < 0.05. 
 
3. Results 
 
3.1. Presence of PPARγ receptor in Jurkat cells 
 
Jurkat cells have previously been demonstrated to express the PPARγ nuclear hormone 
receptor [16]. The presence of the PPARγ protein in the Jurkat E6.1 strain of cells used for these 
experiments was confirmed by Western blot (see supplemental information). Nuclear extracts of 
untreated Jurkats were incubated with polycolonal PPARγ antibodies from 1 μg/mL to 4 μg/mL 
following standard Western blot procedures. Analysis of Jurkat cell nuclear extracts confirmed 
the expression of PPARγ receptor in Jurkat E6.1 cells. A signal of 56 kDa is seen at 1 μg/mL that 
grows in intensity with increasing PPARγ antibody concentration. These results demonstrate that 
PPARγ protein is expressed in the E6.1 strain of Jurkat cells used in this study. 
 
3.2. The PPARγ selective antagonist T0070907 attenuates the IL-2 inhibition induced by 
undecaenediynoic acid isobutylamide at suboptimal Jurkat stimulation 
 
To assess the response of T cells to undecaenediynoic acid isobutylamide (Fig. 1), suboptimal 
IL-2 stimulation of Jurkats by PMA/PHA (PMA 1.25 ng/mL & PHA 0.25 μg/mL) was used. 
Previous work has used this model system to demonstrate that PPARγ mediates IL-2 inhibition 
in T cells [7], [8], [16]. Cells were serum starved for 7 h, plated and then exposed to vehicle 
control (EtOH/DMSO), positive control (TZD-a selective PPARγ agonist), positive control with 
antagonist (TZD/T0070907), undecaenediynoic acid isobutylamide or undecaenediynoic acid 
isobutylamide with antagonist (UDA/T0070907) at increasing concentrations. T0070907 was 
held at constant concentration (2.5 μM). After 18 h incubation, ELISA of the supernatants 
collected from wells treated with the various conditions was performed. Results demonstrate that 
undecaenediynoic acid isobutylamide dose-dependently inhibits IL-2 production beginning at 
0.33 μg/mL (1.4 μM) (Fig. 2). When the selective PPARγ antagonist T0070907 is added with 
undecaenediynoic acid isobutylamide, a dose-dependent attenuation of the IL-2 inhibition is seen 
starting at 0.33 μg/mL. At this concentration, the IL-2 level returns to baseline in the wells 
treated with T0070907. However, at higher levels of undecaenediynoic acid isobutylamide 
treatment, the antagonistic effect of T0070907 on IL-2 secretion is lost, as would be expected in 
increasing concentrations of a competitive agonist and a fixed concentration of antagonist. 
 
 
Fig. 2. PPAR-γ antagonist T0070907 attenuated the undecaenediynoic acid isobutylamide 
(UDA) induced inhibition of IL-2 secretion by suboptimally stimulated Jurkat E6.1 cells. Cells 
were subjected to suboptimal mitogenic stimulation (PMA 1.25 ng/mL, PHA 0.25 μg/mL) after 
serum starvation, for induction of IL-2 in all cases except in the no treatment group (No Tx). The 
selective agonist troglitazone (TZD) represents a positive control (black bar). Stripped bars 
represents the combination of 2.5 μM of T0070907 with the matched treatments (vehicle-VC, 
undecaenediynoic acid isobutylamide, TZD) shown in the left bar of each pair. Results show a 
dose dependent response of IL-2 by undecaenediynoic acid isobutylamide and the positive 
control TZD. The T0070907 treatments dose-dependently attenuate the IL-2 inhibition (up to 
1 μg/mL undecaenediynoic acid isobutylamide) that occurs upon treatment of Jurkat cells with 
increasing doses of undecaenediynoic acid isobutylamide (grey bars). The positive control (TZD 
black bar), also shows significant inhibition of IL-2 which is blocked by T0070907. Values are 
mean + S.E. of experiments performed in triplicate. One-way ANOVA was used to determine 
statistical significance between the vehicle (VC) versus the various treatments 
(undecaenediynoic acid isobutylamide or TZD) treated groups (*p < 0.05) and the 
undecaenediynoic acid isobutylamide versus the undecaenediynoic acid 
isobutylamide/T0070907 treated groups (†p < 0.05). 
 
3.3. Cell survival of Jurkats after treatment with undecaenediynoic acid isobutylamide and 
undecaenediynoic acid isobutylamide/T0070907 does not account for IL-2 modulation 
 
We next determined if the IL-2 changes seen in Jurkats treated in the experimental conditions 
were due to the effects of undecaenediynoic acid isobutylamide and undecaenediynoic acid 
isobutylamide/T0070907 and not due to significant changes in cell number under these treatment 
conditions. Cells from the same treatment conditions in the same experiment in which 
supernatants were harvested for IL-2 ELISA were assayed for cell viability by the XTT assay. A 
statistically significant (p < 0.05) proliferative effect of undecaenediynoic acid isobutylamide on 
the Jurkat E6.1 cells was observed (Fig. 3). Thus, the IL-2 inhibition induced by 
undecaenediynoic acid isobutylamide is not due to cell death, as IL-2 inhibition occurs despite 
the increase in cell number. In addition, these data demonstrate that the increase in IL-2 
concentration observed in wells of Jurkat cells treated with the PPARγ selective antagonist 
T0070907 are not due to an increase in cell number. 
 
 
Fig. 3. Cell survival assay (XTT assay) of Jurkat E6.1 cells treated with undecaenediynoic acid 
isobutylamide (UDA) and T0070907. Cells were subjected to identical conditions as the IL-2 
assays. The selective agonist troglitazone (TZD) represents a positive control (black bar). 
Stripped bars represent the combination of 2.5 μM of T0070907 with the matched treatments 
(vehicle-VC; undecaenediynoic acid isobutylamide; or TZD) shown in the left bar of each pair. 
A proliferative effect by undecaenediynoic acid isobutylamide (grey bars) on Jurkat cells is 
observed. A trend showing inhibition of proliferative effects is observed with the addition of the 
selective PPARγ antagonist T0070907. The positive control, selective PPARγ agonist TZD 
combined with T0070907, shows a statistically significant inhibition of proliferation as 
compared to TZD alone (black bar). One-way ANOVA was used to determine statistical 
significance between the vehicle (VC) versus the undecaenediynoic acid isobutylamide — or 
TZD-treated groups (*p < 0.05), and the undecaenediynoic acid isobutylamide versus the 
undecaenediynoic acid isobutylamide/T0070907 treated groups (†p < 0.05). 
 
3.4. Treatment of 3T3-L1 preadipocytes with undecaenediynoic acid isobutylamide indicates 
PPARγ involvement 
 
The 3T3-L1 cell line, which is PPARγ dependent for differentiation into adipocytes, has been 
widely established as a model to probe for PPARγ activity [17], [18]. To verify PPARγ 
involvement in the inhibition of IL-2 by undecadiynoic acid in T cells, 3T3-L1 differentiation in 
the presence of controls or undecaenediynoic acid isobutylamide was analyzed to confirm that 
this alkylamide is able to induce PPARγ-dependent preadipocyte differentiation. 
 
3T3-L1 cells were grown to confluence and then exposed to experimental conditions including 
the TZD positive control (10 μM), insulin negative control (10 μg/mL), vehicle control, or 
treatment with undecaenediynoic acid isobutylamide (+ insulin 10 μg/mL) at increasing 
concentrations (5.0 μg/mL, 7.5 μg/mL and 10 μg/mL). 
 
Differentiation was assessed morphologically by the relatively round shape of the adipocytes and 
by the presence of the obvious prominent lipid vacuoles seen by microscopy. The vehicle control 
(VC) and the insulin control exhibit no differentiation, while undecaenediynoic acid 
isobutylamide induced a dose dependent adipogenesis in 3T3-L1 cells that was morphologically 
indistinguishable from that induced by the selective PPARγ agonist positive control (TZD) 
(Fig. 4). 
 
 
Fig. 4. Dose-dependent response of 3T3-L1 cell differentiation by undeca-2E-ene-8,10-diynoic 
acid (UDA). Increasing concentrations of UDA enhance 3T3-L1 differentiation, as observed by 
microscopy. 3T3-L1 cells were plated in 6 well plates with 1.5 mL of medium and grown to 
confluence over 5 days. After confluence was achieved, UDA, insulin positive control 
(10 μg/mL), TZD (10 μM), or vehicle control (EtOH/DMSO) were added. Medium and 
treatment conditions were replenished every 2 days after PBS wash. Photomicrographs were 
taken using an Olympus inverted microscope at day 5. Results shown are representative of 
triplicate experiments. 
 
4. Discussion 
 
PPARγ plays a role in a variety of diseases including diabetes, atherosclerosis, inflammation, 
cancer and autoimmune disorders [19], [20], [21], [22], [23]. Thus, novel PPARγ ligands may 
offer further therapeutic options for a wide array of diseases. PPARγ ligands include fatty acid 
derivatives, as well as the selective PPARγ agonists known as the thiazolidinediones (TZDs). 
Both classes of compounds have been shown to reduce IL-2 levels in T 
cells [6], [16], [24], [25], [26]. This effect has been shown via reporter assays to be due to the 
PPARγ nuclear receptor [8]. Moreover, endocannabinoids, which share common structure with 
some of the unsaturated alkylamides, have been shown to reduce IL-2 levels via PPARγ [7], [8]. 
 
While cannabinoid 2 receptor (CB2) activity has been shown for the 2,4-diene olefinic 
alkylamides, the 2-ene alkylamide undecaenediynoic acid isobutylamide (Fig. 1) has shown 
relatively no affinity for CB2 [11]. With this in mind, we probed for PPARγ activity with 
undecaenediynoic acid isobutylamide. The effect of undecaenediynoic acid isobutylamide 
treatment on PPARγ activation was assessed using two well established PPARγ mediated 
biological responses, IL-2 production and PPARγ-dependent adipogenesis in 3T3-L1 cells. 
 
As shown in Fig. 2, the selective PPARγ antagonist T0070907 at 2.5 μM is effective in 
attenuating the IL-2 inhibitory effects of undecaenediynoic acid isobutylamide at alkylamide 
concentrations between 330 ng/mL and 1 μg/mL. This is in range of relevant physiological 
alkylamide concentrations based on in vivo human pharmacokinetic data [27]. T0070907 appears 
to lose its ability to attenuate the IL-2 inhibition at higher concentrations of undecaenediynoic 
acid isobutylamide. This apparent loss of antagonist activity is an expected observation of 
competitive agonism. The fixed dose of T0070907 (2.5 μM) appears to be overwhelmed by 
increasing concentrations of undecaenediynoic acid isobutylamide ranging two orders of 
magnitude. It is also possible that at high undecaenediynoic acid isobutylamide concentrations, 
IL-2 inhibition occurs independently of PPARγ activity. Alternatively, recent data suggests that 
the PPARγ receptor, which presents a particularly large binding cavity as compared to other 
nuclear receptors, may bind more than one ligand at a time[26]. For example, rosiglitazone, a 
selective PPARγ agonist structurally similar to the agonist used in these studies, occupies only 
about 40% of the ligand-binding site in the ternary complex of PPARγ, leaving adequate room 
for other ligands [28]. Crystal structures of PPARγ demonstrate that PPARγ can bind two 9-(S)-
hydroxyoctadecadienoic acid molecules concurrently [29]. Thus a more involved explanation of 
the loss of the antagonism by T0070907 at higher undecaenediynoic acid isobutylamide 
concentrations may be that PPARγ is binding both T0070907 and undecaenediynoic acid 
isobutylamide at the same time and this may result in an overall IL-2 inhibitory effect. It is also 
possible these results could be explained by undecaenediynoic acid isobutylamide acting as a 
partial agonist, as most recently suggested for the alkylamide hexadeca-2E,9Z,12Z,14E-
tetraenoic acid isobutylamide in a fibroblast in vitro model [13]. 
 
Undecaenediynoic acid isobutylamide, is considered a 2-ene alkylamide, which commonly 
contain diacetylinic tails, and are more characteristic of the alkylamides found in E. angustifolia. 
This is opposed to the 2,4-diene alkylamides, more commonly found in E. purpurea, which are 
more commonly olefinic alkylamides. However, both Echinacea species contain olefinic and 
acetylinic classes of alkylamides [30]. The olefinic 2,4-dienes have demonstrated moderate to 
high CB2 affinity, while the diacetylinic 2-enes have thus far, with few exceptions, demonstrated 
negligible CB2 affinity [11]. Considering Christensen's et al. [13] recent work demonstrating 
activation of PPARγ in fibroblasts with olefinic alkylamides at high concentrations (40–100 μM) 
and our results showing PPARγ activation at much lower concentrations (1.4–14 μM) with a 
diacetylinic alkylamide, it is possible that other diacetylinic alkylamides which have lower 
affinities for CB2 than the olefinic alkylamides, may activate PPARγ. 
 
Accordingly, it may be that E. angustifolia and E. purpurea differ in the degree of PPARγ and 
CB2 mediated immunomodulation. Previous studies report that the alkylamide investigated here, 
undecaenediynoic acid isobutylamide, comprises 5% of the alkylamide content of E. angustifolia 
root [31]. Furthermore, up to 55% of E. angustifolia alkylamides possess a diacetylenic tail like 
that of undecaenediynoic acid isobutylamide [32]. This is in contrast to E. purpurea root, which 
does not contain undecaenediynoic acid isobutylamide in detectable concentrations [30], and 
contains less than 45% diacetylenic alkylamides overall [31]. Of interest, previous reports by the 
eclectic physicians of the early-mid 19th to mid 20th century, who brought Echinacea into 
clinical practice, suggested that the two species differed in effect [33]. Further research is needed 
to evaluate how E. angustifolia and E. purpurea vary in their effects, possibly due to differential 
actions on pathways such as PPARγ and CB2. 
 
Our results should be interpreted carefully. There are other proteins known to directly influence 
adipocyte differentiation other than PPARγ. This includes CCAAT/enhancer binding proteins 
(C/EBP), and the basic helix-loop-helix-leucine zipper transcription factor sterol regulator 
element-binding-protein-1c [29]. Furthermore, activation of C/EBP is known to engage the 
PPARγ pathways in both 3T3-L1 cells [34] and T cells [35]. Of particular relevance, a recent 
gene expression study using microarrays suggested C/EBPβ is an upstream activation node for 
many of the pathways activated by Echinacea [29]. It remains to be determined whether C/EBPβ 
plays a role in the PPARγ dependent alkylamide interactions reported here. 
 
In summary, these experiments illustrate the involvement of PPARγ in the inhibition of IL-2 
secretion by T cells in response to undeca-2-ene-8,10-diynoic acid isobutylamide. We 
demonstrate a decrease in IL-2 levels in this model system starting at 330 ng/mL of undeca-2E-
ene-8,10-diynoic acid isobutylamide, which is reversed by the addition of a PPARγ selective 
antagonist. However, the possibility that other targets are involved in this effect is not ruled out 
by these data. Thus, it is possible that there is a combination of effects due to PPARγ and other 
targets that inhibit IL-2 production and induce adipocyte differentiation. These results, coupled 
with previous results demonstrating cannabinoid activity of the alkylamides, suggest that the 
immunomodulatory potential of the alkylamides is likely due to polyvalent actions. Further 
investigations are needed to elucidate the role of PPARγ and other potential alkylamide targets in 
the IL-2 inhibitory response of T cells to undecaenediynoic acid isobutylamide. 
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Figure 1.  
Immunodetection of PPAR-γ in Jurkat cells by Western blotting. Nuclear extracts of untreated Jurkat 
E6.1 cells were treated with rabbit polyclonal PPARγ antibody from 1 µg/mL to 4 µg/mL. A band at 55 
kDa, which increases in intensity with increasing PPAR- γ antibody, confirms the expression of the PPAR-
γ nuclear protein in these cells. Sizes of the marker proteins are shown on the right hand side of the 
blot. 
 
